US-based drug maker Eli Lilly (NYSE:LLY) said on Thursday that is suing six more entities that are accused of selling counterfeit Mounjaro, Reuters reported on Thursday.
Medical spas and wellness centres are among the businesses facing legal action for allegedly selling products claimed to contain tirzepatide, the active ingredient in Lilly's diabetes drug Mounjaro.
Eli Lilly is the only company that has been approved by US Food and Drug Administration to sell the drug.
Lilly has also warned consumers against the use of counterfeit, fake, compounded, and any other unsafe or untested versions of what is claimed to be tirzepatide.
Amylyx receives EU Orphan Drug Designation for Wolfram syndrome treatment
KVK Tech registers Lomaira 8mg tablets in Mexico
GSK's Arexvy receives positive CHMP opinion for at-risk adults aged 50-59
M8 Pharmaceuticals signs exclusive licensing and distribution agreement with LG Chem
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
StimAire names new chief operating officer
TME Pharma to monetise clinical asset NOX-E36 for ophthalmology
Genentech reports positive Phase I Results for oral GLP-1 agonist CT-996